Objective: To investigate the association between antenatal maternal corticosteroid administration and blood levels of reactive oxygen intermediates (ROI), reduced glutathione (GR) and interleukin-6 (IL-6) in preterm, very low birth weight infants.
Introduction
Antenatal corticosteroid treatment is recommended for expectant mothers at risk of premature labor before 34 weeks' gestation and is effective for accelerating maturation of the fetal lungs. 1 Systematic reviews have demonstrated that it is associated with a reduction in global neonatal mortality and reduced risk of respiratory distress syndrome, of necrotizing enterocolitis and of periventricular and intraventricular hemorrhage. Furthermore, administration of this drug does not increase maternal risk of chorioamnionitis or puerperal sepsis. 2, 3 The steroids exert this protective function in the fetus/ newborn (NB) through a variety of mechanisms, both anatomic and related to influence over enzymatic systems.
One of the drug's effects impacts free radical production.
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of oxidative stress and inflammation in umbilical cord blood from very low birth weight preterm newborn infants Jamil P. S. Caldas, 1 Maria M. S. Vilela, 2 Carolina A. Braghini, 3 Tais N. Mazzola, 4 Sérgio T. M. Marba 5 Newborns, especially preterm NB, are highly susceptible to tissue and organ damage from free radicals, in particular from oxygen-derived radicals, and superoxide anions are the most important type of intermediate oxygen radicals
reactive oxygen intermediates (ROI), produced in response to hypoxic-ischemic or inflammatory stimuli. 4, 5 Furthermore, gestation is itself a physiological state in which metabolic demands and tissue oxygen requirements are increased and, in the event that gestational abnormalities occur, there may be oxidative imbalances with excess free radicals that can damage the fetus, which already has a deficient antioxidant defense system. 6 With relation to this aspect, it is important to point out that production of the principal intracellular antioxidant component, glutathione, only peaks at the end of gestation. 7 Several experimental studies have demonstrated the action of corticosteroids on production of reactive oxygen species. Dandona et al. 8 demonstrated that, in adults, a single injection of hydrocortisone was capable of causing a significant reduction in the production of free radicals derived from O 2 , reaching a low point between 2 and 8 hours after administration and returning to normal after 24 hours.
A study using preterm newborn lambs that had been given betamethasone during the antenatal period demonstrated that this steroid provoked a reduction in production of hydrogen peroxide and interleukin-6 (IL-6) and diminished phagocytosis capacity. These effects were time dependent and were no longer observed 7 days after administration. 9 During the last twenty years it has also been demonstrated that there is a close relationship between mediators of oxidative stress and biochemical markers of inflammation, such as the interleukins, with the observation of a reciprocal effect of induction of synthesis of free radicals and inflammatory mediators. 5, 10 Nevertheless, the effect of steroids administered to the mother on fetal production of ROI by polymorphonuclear leukocytes has not yet been studied in human beings.
Improved understanding of the pathophysiologic mechanisms involved in the effects of antenatal corticosteroid treatment is important for defining potential targets for efforts to reduce or even prevent the harmful consequences of free radical activity. 11 Therefore, the objective of this study was to investigate the association between antenatal administration of corticosteroid to the mother and blood ROI, reduced glutathione (GR) and IL-6 concentrations in preterm, very low birth weight NB.
Methodology
This was a cohort study that recruited all preterm NB born live with birth weight of less than 1,500 g at a tertiary This analysis therefore compared two groups: "ACT yes"
containing mothers who had had the drug and "ACT no" containing those who hadn't. A complete treatment cycle was defined as when an expectant mother was given two 12 mg doses of betamethasone with a 24-hour interval and the child was born at least 24 hours after the second dose of medication. An incomplete cycle was defined as when the mother was given both doses, but the birth took place less than 24 hours after the second dose of betamethasone. Therefore, mothers who were only given one dose of betamethasone were only assessed in the first analysis.
The maximum time between steroid administration and birth was set at 7 days. and three of triplets). As the inclusion criteria was birth weight, not all of the children from the multiple births were recruited, since seven of these infants had birth weight over the 1,500 g limit. None of the parents refused permission for the cord blood samples.
In all cases the corticosteroid used was betamethasone.
It was observed that 92/111 (82.88%) of the mothers were given the drug. Sixteen of them (17.4%) only received one dose of betamethasone before their child was born, and 82.60% were given the full cycle.
The antenatal betamethasone group and no antenatal betamethasone group were compared with each other and there were no differences in terms of maternal variables or birth variables, with the exception of vaginal delivery, which was significantly associated with no treatment (p = 0.04 and relative risk = 1.549, 95%CI 1.048-2.288).
There were no significant associations between antenatal betamethasone use and the neonatal variables analyzed (Table 1 ). There were no statistically significant differences for any of the maternal or neonatal variables that could alter the levels of the blood markers studied.
Problems with the cord blood samples meant that not all of the 125 biochemical assays of ROI, GR and IL-6 could be performed. Coagulation prevented ROI and GR assays and hemolysis prevented IL-6 assays. A total of 98 samples were assayed for baseline ROI, 99 for stimulated ROI, 100
for GR and 121 for IL-6.
With regard to the effect of antenatal corticosteroid administration on the blood levels of these markers, there
were statistically significant differences in the median test results when divided into groups administered and not administered the drug, irrespective of time or dose. When mothers were given the full betamethasone cycle, however, there were significant reductions in median baseline ROI and in median IL-6 (Tables 2 and 3) . A high test power was obtained for analysis of baseline ROI and for IL-6 production when the full ACT cycle was used.
Discussion
In this study 83% of the mothers had been given to 57%. 17 This improvement at the institution studied has been made possible by the efforts of the local obstetrics team to offer the treatment to all expectant mothers who at risk of premature delivery before 34 weeks' gestation, associated or not with tocolytics. [18] [19] [20] The decision to define a "complete cycle" as two doses of betamethasone with a 24-hour interval between them and a further 24-hour interval prior to birth was arbitrary.
There is no consensus in the literature on the optimum time needed for the drug to act, although it is recommended that the mother be given two doses of betamethasone. Since this study was investigating the effect of the medication on biochemical markers and not on clinical variables, we hypothesized that there would be a minimum time needed Results shown are median (p25-p75). Glutathione results in mg%. IL-6 = interleukin-6 (pg/ml); ROI = reactive oxygen intermediates (nMol/10 6 cells). * Mann-Whitney test.
for it to take effect. Since there are no references in the literature that state what this "optimum" time might be, we chose 24 hours as the cutoff. Therefore, mothers who were given only one dose of betamethasone were only included in the analysis that differentiated mothers given ACT from mothers not given ACT.
When we evaluated the effect of betamethasone administration on ROI, GR and IL-6 production, we observed that it only had an effect when the cycle was completed.
Baseline ROI and IL-6 production was significantly suppressed by betamethasone administration when the mother was given both doses and birth took place at least 24 hours after the second dose. This implies that the effect of the drug is time-dependent.
This suppressive effect can be considered positive to the extent that the drug suppresses part of the oxidative and inflammatory stress to which the fetus is subjected during labor of premature delivery, resulting in a premature neonatal transition that is less unbalanced and therefore less subject to severe hemodynamic disorders.
The inhibitory effect of steroids on ROI production does not imply a negative immunosuppressor effect, but works as an immunomodulator, since intercurrent conditions during gestation and delivery can be associated with
Antenatal betamethasone neonatal oxidative stress -Caldas JP et al. were added to the culture. 23 It is possible that an increased sample size could be needed to verify whether this finding would be maintained, since the statistical power of the sample was below 80%.
On the other hand, one could also argue that since this was in vitro stimulation it does not reflect the complex conditions of biological in vivo stimuli. Furthermore, the functions of neutrophils change as they move from the circulation into tissues. 23, 24 We did not observe any suppressive effect of betamethasone on glutathione production. This finding could be considered protective, since the absence of attenuation of this system that neutralized free radicals of oxygen in combination with reduced production of superoxide radicals, should mean there are less chances of oxidative injuries to the fetus/NB. Furthermore, the absence of suppression is beneficial given that glutathione levels drop off rapidly during the first days of life of preterm NB because of the increased oxidative stress associated with birth. 25, 26 Notwithstanding, the low statistical power does not permit extrapolation of these results and a larger sample is required to better assess this effect.
Interleukin-6 is thought to be the principal cytokine involved in fetal inflammatory response syndrome, which is even defined on the basis of serum cytokine levels in combination with chorioamnionitis and funisitis. 27, 28 The effects of antenatal betamethasone on fetal IL-6 production have been little studied. Kavelaars et al. 29 failed to detect suppression of IL-6 synthesis in cells from the umbilical cords of full term and preterm human fetuses. However, Kramer et al. 9 conducted experimental studies using with neutrophils from full-term lambs and demonstrated that betamethasone administered to the mother suppressed IL-6 production 15 hours later.
Arad et al. 30 showed that when the drug was administered to women during premature labor, it was associated with a lower number of NB with elevated IL-6 levels (defined as > 11 pg/mL).
In our study there was a significant association between umbilical serum IL-6 levels and administration of a complete betamethasone cycle to the mother, which could be because this is the in vivo effect, in the presence of other active stimulants that are absent in cell culture conditions. This One limitation of our study is that the analyses were performed on cord blood samples, which reflects the perinatal conditions related to premature birth. This study design was chosen since the objective was to assess the fetal effects of betamethasone administered to the mother.
Notwithstanding, a comparison of the same markers assayed in postnatal blood would be a valuable contribution, since the drug still exerts a variable degree of effect at this point and it would be of use o investigate the effects of birth and of extrauterine conditions on inflammatory mediators and oxidative stress.
Another limitation to our study is that the statistical power was inadequate for some of the analyses since the original sample size calculation was based on the clinical outcome of periventricular and intraventricular hemorrhage.
Therefore, the biochemical effect on ROI and IL-6 production of corticosteroid administered to the mother could be the factor that determines the protection conferred by the drug against neonatal diseases that are associated with oxidative stress and inflammation, such as periventricular and intraventricular hemorrhage and early hemodynamic disorders.
In summary, administration of a complete betamethasone cycle to the mother had a suppressive effect on baseline ROI production and on IL-6 production in preterm very low weight NB. Therefore, this study serves as a basis for evaluation of antenatal corticosteroid use, of the markers studied and of the clinical progress of these NB, especially with relation to diseases caused by the action of free radicals and intrauterine inflammation.
